View Item 

Show simple item record

Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
dc.contributor.authorThall, Peter F.en_US
dc.contributor.authorNguyen, Hoang Q.en_US
dc.contributor.authorBraun, Thomas M.en_US
dc.contributor.authorQazilbash, Muzaffar H.en_US
dc.date.accessioned2013-12-04T18:57:42Z
dc.date.available2014-10-06T19:17:43Zen_US
dc.date.issued2013-09en_US
dc.identifier.citationThall, Peter F.; Nguyen, Hoang Q.; Braun, Thomas M.; Qazilbash, Muzaffar H. (2013). "Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes." Biometrics 69(3): 673-682. <http://hdl.handle.net/2027.42/101836>en_US
dc.identifier.issn0006-341Xen_US
dc.identifier.issn1541-0420en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/101836
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherPhase I/II Clinical Trialen_US
dc.subject.otherStem Cell Transplantationen_US
dc.subject.otherAdaptive Decision Makingen_US
dc.subject.otherBayesian Designen_US
dc.subject.otherUtilityen_US
dc.titleUsing Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMathematicsen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23957592en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/101836/1/biom12065-sm-0001-SuppData.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/101836/2/biom12065.pdf
dc.identifier.doi10.1111/biom.12065en_US
dc.identifier.sourceBiometricsen_US
dc.identifier.citedreferenceYuan, Y. and Yin, G. ( 2009 ), Bayesian dose‐finding by jointly modeling toxicity and efficacy as time‐to‐event outcomes. Journal of the Royal Statistical Society, Series C 58, 954 – 968.en_US
dc.identifier.citedreferenceZhang, W., Sargent, D.J. and Mandrekar, S. ( 2006 ), An adaptivedose‐finding design incorporating both efficacy and toxicity. Statistics In Medicine 25, 2365 – 2383.en_US
dc.identifier.citedreferenceAzriel, D., Mandel, M., and Rinott, Y. ( 2011 ). The treatment versus experimentation dilemma in dose‐finding studies. Journal of Statistical Planning and Inference 141, 2759 – 2758.en_US
dc.identifier.citedreferenceBekele, B. N., Ji, Y., Shen, Y., and Thall, P. F. ( 2008 ). Monitoring late onset toxicities in phase I trials using predicted risks. Biostatistics 9 442 – 457, 2008en_US
dc.identifier.citedreferenceBraun, T. M. ( 2002 ). The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. Contemporary Clinical Trials 23, 240 – 256.en_US
dc.identifier.citedreferenceBraun, T. M. ( 2010 ). Generalizing the TITE‐CRM to adapt for early‐ and late‐onset toxicities. Statistics in Medicine 25, 2071 – 2083.en_US
dc.identifier.citedreferenceBraun, T.M., Yuan, Z., and Thall, P.F. ( 2005 ). Determining a maximum tolerated schedule of a cytotoxic agent. Biometrics 61, 335 – 343.en_US
dc.identifier.citedreferenceBraun, T. M., Thall, P. F., Nguyen, H., and de Lima, M. ( 2007 ). Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clinical Trials 4, 113 – 124.en_US
dc.identifier.citedreferenceCheung, Y. and Chappell, R. ( 2000 ). Sequential designs for Phase I clinical trials with late‐onset toxicities. Biometrics 56, 1177 – 1182.en_US
dc.identifier.citedreferenceLi, Y., Bekele, B. N., Ji, Y., and Cook, J. D. ( 2008 ). Dose–schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Statistics In Medicine 27, 4895 – 4913.en_US
dc.identifier.citedreferenceNelsen, R. B. ( 2006 ). An Introduction to Copulas, 2nd edition. New York: Springer‐Verlag.en_US
dc.identifier.citedreferenceO'Quigley, J., Pepe, M., and Fisher, L. ( 1990 ). Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46, 33 – 48.en_US
dc.identifier.citedreferenceThall, P. F. ( 2010 ). Bayesian models and decision algorithms for complex early phase clinical trials. Statistical Science 25, 227 – 244.en_US
dc.identifier.citedreferenceThall, P. F. and Cook, J. D. ( 2004 ). Dose‐finding based on efficacy‐toxicity trade‐offs. Biometrics 60, 684 – 693.en_US
dc.identifier.citedreferenceThall, P. F. and Nguyen, H. Q. ( 2012 ). Adaptive randomization to improve utility‐based dose‐finding with bivariate ordinal outcomes. Journal of Biopharmaceutical Statistics 22, 785 – 801.en_US
dc.identifier.citedreferenceThall, P. F. and Russell, K. T. ( 1998 ). A strategy for dose finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54, 251 – 264.en_US
dc.identifier.citedreferenceThall, P. F., Szabo, A., Nguyen, H. Q., Amlie‐Lefond, C. M., and Zaidat, O. O. ( 2011 ), Optimizing the concentration and bolus of a drug delivered by continuous infusion. Biometrics 67, 1638 – 1646.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
biom12065-sm-0001-SuppData.pdf
Size:
136.8KB
Format:
PDF
View/Open
Name:
biom12065.pdf
Size:
291.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.